This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Trial In Patients With Advanced Cancer And Leukemia

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: April 6, 2009
Last updated: April 3, 2017
Last verified: April 2017
This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia

Condition Intervention Phase
Neoplasms by Histologic Type Drug: PF-03084014 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Trial Of Pf-03084014 In Patients With Advanced Solid Tumor Malignancy And T-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Number of participants with Dose-limiting toxicities (DLT) [ Time Frame: 28 days ]
    First cycle dose limiting toxicity (DLT) rate

  • Overall safety profile characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events and any laboratory abnormalities. [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • Concentrations of PF 03084014 and dexamethasone at selected timepoints [ Time Frame: 2 years ]
  • Serum pharmacokinetic parameters of PF-03084014 [ Time Frame: 2 years ]
  • Changes in NICD levels and expression levels of Notch1 target genes [ Time Frame: 28 days ]
  • Objective tumor response, overall response rate, time to tumor progression, progression free survival, and duration of response [ Time Frame: 2 years ]
  • QTc interval [ Time Frame: 2 years ]

Enrollment: 72
Actual Study Start Date: June 2009
Study Completion Date: November 2016
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: PF-03084014
10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
Other Name: gamma secretase inhibitor


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with advanced cancer that is resistant to standard therapy or for which no standard therapy is available
  • Patients with acute T cell leukemia/lymphoblastic lymphoma that is resistant to standard therapy or for which no standard therapy is available
  • Men and women >16 years old

Exclusion Criteria:

  • Prior treatment with a gamma secretase inhibitor for treatment of cancer
  • Patients taking Tamoxifen
  • Patients with active graft versus host disease
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
  • Patients who are pregnant or breast feeding
  • Patients with clinical evidence of central nervous system disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00878189

United States, Colorado
Anschutz Cancer Pavilion
Aurora, Colorado, United States, 80045
University of Colorado Denver CTRC
Aurora, Colorado, United States, 80045
University of Colorado Hospital
Aurora, Colorado, United States, 80045
United States, Massachusetts
Massachusetts General Hospital Clinical Laboratory
Boston, Massachusetts, United States, 02114
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Dana Ferber Cancer institute
Boston, Massachusetts, United States, 02215
United States, Michigan
Karmanos Cancer Center / Wayne State University
Detroit, Michigan, United States, 48201
United States, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030-4009
DIPRTMNT CLIN Scienze RADIOL e Istocitopatologiche
Bologna, Italy, 40138
Istituto di Ematologia Seragnoli
Bologna, Italy, 40138
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Pfizer Identifier: NCT00878189     History of Changes
Other Study ID Numbers: A8641014
2010-022036-36 ( EudraCT Number )
Study First Received: April 6, 2009
Last Updated: April 3, 2017

Keywords provided by Pfizer:
Phase 1 dose escalation study in advanced solid tumor malignancy and leukemia

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms processed this record on August 18, 2017